Abstract: The present invention includes a novel method and system for identification of microorganisms in samples that proteins and other biological material from non-microorganism sources (e.g., proteins of mammalian origin) that can interfere with identification of the microorganisms. The methods and systems described herein include use of a single-use chromatography medium to purify intact proteins prior to mass spectrometry analysis. The chromatography medium and the methods described herein can rapidly and efficiently remove of a substantial portion of interfering biological material (e.g., mammalian proteins) from a crude cell lysate while preserving high signal strength and removing enough of the interfering protein(s) to allow for identification of the microorganism(s) by mass spectrometry analysis.

Abstract: The present invention includes a novel method and system for identification of microorganisms in samples that proteins and other biological material from non-microorganism sources (e.g., proteins of mammalian origin) that can interfere with identification of the microorganisms. The methods and systems described herein include use of a single-use chromatography medium to purify intact proteins prior to mass spectrometry analysis. The chromatography medium and the methods described herein can rapidly and efficiently remove of a substantial portion of interfering biological material (e.g., mammalian proteins) from a crude cell lysate while preserving high signal strength and removing enough of the interfering protein(s) to allow for identification of the microorganism(s) by mass spectrometry analysis.

Abstract: Described are extraction columns and systems that include extraction columns. The extraction column includes a column body that has a reservoir portion, an extraction media portion, and a collar portion. The reservoir portion includes an inlet and a reservoir. The extraction media portion includes an elongated sleeve having an inner surface defining a cavity. The extraction media portion has an inlet end in fluid communication with the reservoir and an outlet end. An extraction medium is disposed in the cavity of the elongated sleeve. The collar portion extends axially in a common direction with the elongated sleeve. The collar portion has a terminal end which is spaced apart from the outlet end of the elongated sleeve and which extends axially at least to a plane defined by the outlet end of the elongated sleeve.

Abstract: Described are extraction columns and systems that include extraction columns. The extraction column includes a column body that has a reservoir portion, an extraction media portion, and a collar portion. The reservoir portion includes an inlet and a reservoir. The extraction media portion includes an elongated sleeve having an inner surface defining a cavity. The extraction media portion has an inlet end in fluid communication with the reservoir and an outlet end. An extraction medium is disposed in the cavity of the elongated sleeve. The collar portion extends axially in a common direction with the elongated sleeve. The collar portion has a terminal end which is spaced apart from the outlet end of the elongated sleeve and which extends axially at least to a plane defined by the outlet end of the elongated sleeve.

Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The present invention relates to a stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of a proteolytic enzyme in the modification of the cell surface of a stem cell. The present invention further relates to a method of modifying the cell surface of a stem cell by treatment with a proteolytic enzyme.

Abstract: A complex of Tra-antibody bound to an isolated glycan comprising type I—N-acetyllactosamine comprising target structure, and methods and uses utilizing said complex.

Abstract: The invention describes novel reagents that can be applied for analysis of the quality of human cells. The method evaluates the integrity of the plasma membrane of the cells by detecting novel glyco structures found only intracellularly. The method can be applied, for example, to demonstrate exposure of therapeutic cell preparation to potentially harmful conditions. It can also be used as a quality control tool in methods in which intact cell membrane is essential and it can be applied in separation of damaged cells from non- damaged.

Abstract: The invention is directed to a method and kit to control and modify the status of cells, such as human stem cells, by changing their glycosylation, in particular sialylation and fucosylation, levels in a reaction condition where culture medium reagents, such as divalent cations, are present and cells are kept non-adherent. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered.

Abstract: The invention is directed to the analysis of novel acidic glycan markers of several types of human cells. The analysis is performed by mass spectrometry or specific binder molecules.

Abstract: This invention relates to antibody engineering technology. More particularly, the present invention relates to human IgM antibodies and derivatives thereof, which have novel binding specificity with regard to several oligosaccharide sequences and/or xenoantigenic sialic acid residue. The present invention also relates to processes for making and engineering such novel saccharide and/or NeuGc-binding monoclonal antibodies and to methods for using these antibodies and derivatives thereof in the field of immunodiagnostics, enabling qualitative and quantitative determination of xenoantigenic NeuGc in biological and raw material samples, as well as in immunotherapy, enabling blocking of xenoantigenic NeuGc in patients.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.

Abstract: The present invention provides methods and materials to modulate and grow stem cells by contacting stem cells with a binder recognizing terminal glycan structures of stem cells. The modulation can be morphological change, change in differentiation status, biological status or adherence. The materials provided in the present invention are also useful to screen such a binding agents and binders.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.

Abstract: The invention describes reagents and methods for specific binders to glycan structures of stem cells. Furthermore the invention is directed to screening of additional binding reagents against specific glycan epitopes on the surfaces of the stem cells. The preferred binders of the glycans structures includes proteins such as enzymes, lectins and antibodies.